A combination treatment based on drug repurposing demonstrates mutation-agnostic efficacy in pre-clinical retinopathy models.
Henri LeinonenJianye ZhangLaurence M OccelliUmair SeemabElliot H ChoiLuis Felipe L P MarinhoJanice QuerubinAlexander V KolesnikovAnna GalinskaKatarzyna KordeckaThanh HoangDominik LewandowskiTimothy T LeeElliott E EinsteinDavid E EinsteinZhiqian DongPhilip D KiserSeth BlackshawVladimir J KefalovMarcin TabakaAndrzej T FoikSimon M Petersen-JonesKrzysztof PalczewskiPublished in: Nature communications (2024)
Inherited retinopathies are devastating diseases that in most cases lack treatment options. Disease-modifying therapies that mitigate pathophysiology regardless of the underlying genetic lesion are desirable due to the diversity of mutations found in such diseases. We tested a systems pharmacology-based strategy that suppresses intracellular cAMP and Ca2+ activity via G protein-coupled receptor (GPCR) modulation using tamsulosin, metoprolol, and bromocriptine coadministration. The treatment improves cone photoreceptor function and slows degeneration in Pde6βrd10 and RhoP23H/WT retinitis pigmentosa mice. Cone degeneration is modestly mitigated after a 7-month-long drug infusion in PDE6A-/- dogs. The treatment also improves rod pathway function in an Rpe65-/- mouse model of Leber congenital amaurosis but does not protect from cone degeneration. RNA-sequencing analyses indicate improved metabolic function in drug-treated Rpe65-/- and rd10 mice. Our data show that catecholaminergic GPCR drug combinations that modify second messenger levels via multiple receptor actions provide a potential disease-modifying therapy against retinal degeneration.